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Editorial on the Research Topic
Special Issue on Innovative Multi-Disciplinary Approaches for Precision Studies in Leukemia
By investigating the role of recurrent mutations, epigenetic modifications and aberrant activation of
oncogenic signaling (1–4), our understanding of leukemogenesis has advanced to the stage that
precision medicine is capable of transforming diagnostic and therapeutic approaches. This Research
Topic focuses on the innovative technologies that will aid in the development of a multi-
dimensional integrated molecular network, enabling the prediction of therapy responses and
creation of novel treatments for those in most clinical need.
Risk stratification scores in AML are important tools for clinicians and scientists alike, due to the
relative ease with which biomarker panels can assist with diagnosis, prediction of prognosis, overall
survival (OS) and guide appropriate treatment choices. Our work has identified a gene signature
associated with the histone demethylase KDM4A, the KDM4A-9 score, which is associated with
poor OS and independent of age, cytogenetic risk and mutation status (2). KDM4A-9 is highly
correlative with the LSC17 score, while having no overlap, showing the collective power of
integrating risk scoring systems (2, 5). In this Research Topic, risk stratification was addressed
by Lu et al. through bioinformatic analysis of the publicly-available databases. The authors explored
the relationship of CXCR family members in AML and found that over-expression of specific CXCR
receptors correlates with FAB subtypes and AML risk stratification. Of note, CXCR2 expression was
identified as an independent prognostic factor. Applying machine learning algorithms to gene
expression datasets, Mosquera Orgueira et al. described a new model containing 123 variables
(ST-123) that was capable of predicting survival of AML patients. Two genes were identified, namely
KDM5B and LAPTM4B, that have an established role in the pathogenesis of myeloid malignancies.
Similarly, Sanchez Corrales et al. reviewed machine learning potential to dissect those heterogeneities
that render AML hard to tackle with effective therapies, by identifying specific leukemic populations
and the biomarkers that define these populations. They propose to design precision immunotherapy
strategies, accounting for the heterogeneous sub-populations characteristic of each disease.
Van Gils et al. offered a comprehensive review of the diverse, mainly non-genetic, mechanisms of
resistance to chemotherapy in AML, from survival pathways mediated by the bone marrow
microenvironment to altered epigenetic profiles and metabolic reprogramming. Unlike most
reviews on the same subject, it focused also on AML “persisters” highlighting that they are notAugust 2021 | Volume 11 | Article 7440091
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may be induced by therapy. Understanding the plasticity of these
mechanisms in different patients could lead to effective
personalized therapy.
Metabolic reprogramming is a key hallmark of cancer and
gaining a fundamental understanding of disease biology in terms
of metabolic profiling may enable personalized therapies that
exploit the unique weaknesses in leukemic cells. As such, Zhang
et al. analyzed publicly-available databases to investigate
metabolism-related prognostic factors and identified four genes
(PLA2G4A, HMOX2, AK1, SMPD3) that when highly expressed
represented a poor prognostic predictor forAMLpatients. Dembitz
and Gallipoli described recent evidence demonstrating the validity
ofdeveloping therapies that targetmetabolic pathways inAML.The
review highlights the differential metabolic pathways that are
present in distinct AML subtypes and disease stages, which may
enable truly personalized treatments for these patients, supported
by FDA approval of the first metabolic inhibitors targeting IDH1/2
in AML. Further promising avenues for targeting metabolic
pathways are discussed.
The impact that the microenvironmental niche has on tumor
persistence is now becoming appreciated, and as such the
stromal component of the leukemic niche may represent a
novel therapeutic target, as has been demonstrated in B cell
malignancies (6). Two reports tackled different angles of this
important topic. Sletta et al. explored the role of colony
st imulat ing factor 1R (CSF1R) within the stromal
compartment. High levels of CSF1R are associated with shorter
patient survival in AML and RUNX1, a key driver of AML,
regulates CSF1R. This review assessed the role of CSFR1 in
immunoregulation of macrophage function/polarization and
discussed recent pre-clinical studies and clinical trials
incorporating distinct CSFR1 inhibitors, providing evidence to
support the use of CSF1R-targeted therapies in AML. Simioni
et al. reviewed the role of the tumor microenvironment in acute
lymphoblastic leukemia. The authors summarized the main
aspects concerning experimental, pre-clinical and clinical
information in the field, highlighting the potential of
therapeutic strategies, which include cytokines and cytokines
receptors, such as CXCL12/CXCR4, the MEK/ERK and PI3K/
AKT signaling networks. The importance of oncogenic signaling
is highlighted also in a review by Ratti et al., that provided an in
depth description of the role of phosphoinositide (PI) lipid
second messengers in the oncogenesis of AML. The authors
emphasize key enzymes in PI metabolism, which are emerging as
putative druggable targets in leukemia. They suggest that
combining bioinformatic analysis with PI pathsway targeting
can lead to new combination therapies to reprogramFrontiers in Oncology | www.frontiersin.org 2transcriptional output, control the cell state and attenuate
uncontrolled AML cell growth.
Finally, Sun et al. present data from a clinical trial
(NCT03412409) in which older patients with acute leukemia
or MDS underwent haploidentical-SCT using a novel
conditioning regime. Hematopoietic stem cell transplantation
(SCT) represents a potential cure for acute leukemia, however as
most hematological malignancies occur in older individuals, in
which the myeloablative conditioning regimen prior to SCT is
linked to a high risk of treatment-related mortality (TRM), this is
not always possible. Incorporating reduced intensity conditioning
(low dose fludarabine and reduced cyclophosphamide) in patients
with acute leukemia/MDS of ≥55 years old revealed that OS,
leukemia free survival, TRM, and cumulative incidence of relapse
were comparable to a historical, younger cohort of patients that
underwent the normal conditioning regimen. This small study
suggests that a reduction in the conditioning regimen prior to
SCT may be a feasible option for older acute leukemia patients.
Although the treatment of leukemia in all its forms still
represents a significant challenge, these articles all highlight
novel methods/strategies that can be utilized to identify
targets/biomarkers that enable scientists and clinicians the
opportunity to develop novel stratified diagnostics or
therapeutic interventions for specific patient cohorts. As the
development of ‘omics approaches is a highly competitive and
fast-moving field, an ongoing challenge will be how to integrate
individual approaches into a robust multi-omics-based platform
that can be used as a routine clinical and diagnostic tool to form
the basis of digital healthcare. Indeed, artificial intelligence-lead
machine learning technologies, collecting and analyzing
molecular-level ‘omics information, will represent the forefront
of innovation in personalized therapy for prevention and early
detection of diseases such as leukemia, coupled with precision
prognosis and personalized treatment pathways.AUTHOR CONTRIBUTIONS
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